Dr. Vandross is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
805 west 37th
Austin, TX 78705
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Yale-New Haven Medical CenterResidency, Internal Medicine, 2011 - 2014- Yale-New Haven Medical CenterResidency, Surgery, 2009 - 2011
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2009
Certifications & Licensure
TX State Medical License 2020 - 2026
CA State Medical License 2014 - 2020- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 12 citationsCase Reports in the Age of TwitterAdam S. Cifu, Andrae Vandross, Vinay Prasad
The American Journal of Medicine. 2019-10-01 - 12 citationsAtypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition.Ramy M Hanna, Marina Barsoum, Andrae Vandross, Ira B Kurtz, Richard M. Burwick
Current Opinion in Nephrology and Hypertension. 2019-05-01 - 4 citationsProteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma.Andrae Vandross
Seminars in Oncology. 2018-01-01
Press Mentions
Chemo-IO over IO Alone in Patients with Advanced NSCLCJuly 13th, 2021- Genomic Test in Lung Cancer: Waiting Is the Hardest PartJuly 6th, 2021
- What the New KRAS Inhibitor Means for Lung CancerJune 29th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
